Advertisement
E-poster session SaaG: Cholesterol efflux and reverse cholesterol transport| Volume 287, e56-e57, August 2019

Treatment With 2-Hydroxypropyl-Β-Cyclodextrin Induces Macrophage Cholesterol Efflux In Vitro But Does Not Induce Lesion Regression In Apoe Knockout Mice In Vivo

Published:August 03, 2019DOI:https://doi.org/10.1016/j.atherosclerosis.2019.06.160
Treatment With 2-Hydroxypropyl-Β-Cyclodextrin Induces Macrophage Cholesterol Efflux In Vitro But Does Not Induce Lesion Regression In Apoe Knockout Mice In Vivo
Previous ArticleThe Saturated Fatty Acids Palmitic Acid And Stearic Acid Do Not Differently Affect Cholesterol Efflux Capacity: Results Of A Human Dietary Intervention Trial
Next ArticleDietary Sargassum Fusiforme Improves Memory And Reduces Amyloid Plaque Load In An Alzheimer’s Disease Mouse Model
      Background and Aims: Macrophage cholesterol efflux is considered a therapeutic target to reduce atherosclerosis susceptibility and induce atherosclerotic lesion regression. 2-hydroxypropyl-β-cyclodextrin (CD) has been suggested to remove cholesterol from cells. In this study, we investigated the effect of CD treatment on macrophage cholesterol efflux in vitro and the ability of established lesions to regress in response to lipid lowering.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Atherosclerosis
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Register: Create an account
      Institutional Access: Sign in to ScienceDirect

      Article info

      Publication history

      Published online: August 03, 2019
      EAS19-0738

      Identification

      DOI: https://doi.org/10.1016/j.atherosclerosis.2019.06.160

      Copyright

      © 2019 Published by Elsevier Inc.

      ScienceDirect

      Access this article on ScienceDirect

      The content on this site is intended for healthcare professionals.


      We use cookies to help provide and enhance our service and tailor content. To update your cookie settings, please visit the Cookie Preference Center for this site.
      Copyright © 2023 Elsevier Inc. except certain content provided by third parties.


      RELX